Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 9.3% gain over the past six months, beating the S&P 500 by 2 percentage points.
36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies
The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early February 2026, the data shows a stark divergence: while the services sector—the primary engine of post-pandemic inflation—is
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.
TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update.
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion. The deal, confirmed on January 20, 2026, represents a significant escalation in the multi-billion dollar race to dominate the
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
